Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MSH6 |
Variant | A1320Sfs*5 |
Impact List | frameshift |
Protein Effect | unknown |
Gene Variant Descriptions | MSH6 A1320Sfs*5 indicates a shift in the reading frame starting at amino acid 1320 and terminating 5 residues downstream causing a premature truncation of the 1360 amino acid Msh6 protein (UniProt.org). A1320Sfs*5 has been identified in the scientific literature (PMID: 35739269, PMID: 33393477, PMID: 18809606), but has not been biochemically characterized and therefore, its effect on Msh6 protein function is unknown (PubMed, Feb 2025). |
Associated Drug Resistance | |
Category Variants Paths |
MSH6 mutant MSH6 A1320Sfs*5 |
Transcript | NM_000179.3 |
gDNA | chr2:g.47806607dupA |
cDNA | c.3957dupA |
Protein | p.A1320Sfs*5 |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001406809.1 | chr2:g.47806607dupA | c.3957dupA | p.A1320Sfs*5 | RefSeq | GRCh38/hg38 |
NM_001406796.1 | chr2:g.47806607dupA | c.3957dupA | p.A1320Sfs*5 | RefSeq | GRCh38/hg38 |
NM_000179.2 | chr2:g.47806607dupA | c.3957dupA | p.A1320Sfs*5 | RefSeq | GRCh38/hg38 |
NM_000179.3 | chr2:g.47806607dupA | c.3957dupA | p.A1320Sfs*5 | RefSeq | GRCh38/hg38 |
NM_001406808.1 | chr2:g.47806607dupA | c.3957dupA | p.A1320Sfs*5 | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|